As the U.S. is the largest pharmaceutical market by revenue, many pharmaceutical manufacturers have dedicated U.S.-specific departments and teams to support new therapy launches.

The U.S. pharmaceutical drug channel is increasingly complex, involving numerous stakeholders and intricate agreements that impact the economics surrounding prescription drugs. The emergence of provider rebate aggregators is one of the more recent examples of this complexity. Their business models are intentionally opaque, and their reach throughout the channel via partnerships has grown significantly in recent years. As a result, it’s critical for manufacturers to understand the prevalence of these entities, and the impact they have on channel economics, particularly to their bottom line.

Navigating the landscape of patient access in the pharma industry has become increasingly complex, extending far beyond traditional channels. The challenges are multifaceted, influenced by evolving policies, innovative payer strategies, and shifts in provider dynamics.